CERUS CORP
For the period ended Jul 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 30, 2026 · Filed Jul 30, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Additional highlights include:
Additional highlights include:
Second-quarter 2026 total revenue comprised of (in millions, except percentages):
| Three Months Ended · Six Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| June 30, · Change · June 30, · Change | ||||||||
| 2026 | 2025 | $ | % | 2026 | 2025 | $ | % | |
| Product Revenue | $57.4 | $52.4 | $5.0 | 10% | $111.1 | $95.7 | $15.4 | 16% |
| Government Contract Revenue | 5.9 | 7.7 | (1.8) | -24% | 12.1 | 13.3 | (1.2) | -9% |
| Total Revenue | $63.3 | $60.1 | $3.2 | 5% | $123.2 | $109.0 | $14.2 | 13% |
| Numbers may not sum due to rounding. Percentages calculated from unrounded figures. | ||||||||
Demand for IFC continued to increase, with second quarter volumes - including kits and finished therapeutic doses (measured in FC15* equivalent units) – up approximately 20% compared to the prior year period. Second quarter U.S. IFC sales totaled $6.7 million, up from $5.6 million in the prior year period.
Submitted PMA for the INTERCEPT Blood System for Platelets with INT200 Illuminator, the Company’s next generation LED-based illumination device, to the FDA as planned. Given review timelines, a regulatory decision is anticipated in early 2027.
Completed debt refinancing, including a $30 million reduction in the outstanding term loan funded with $20 million of cash on hand and $10 million drawn under the new, lower-cost revolving credit facility.
Expanded the Company’s ongoing collaboration with the Biomedical Advanced Research and Development Authority, or BARDA, to further advance the development of the INTERCEPT Red Blood Cell system, increasing the total potential value of the 2024 contract by $21.9 million from $248.6 million to $270.5 million. The BARDA contract is funded in whole or in part with federal funds from the Department of Health and Human Services’ Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority under Contract No. 75A50124C00046.
Cash, cash equivalents, and short-term investments were $56.3 million at June 30, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.